Press Room

CPhI Japan 2024

Start
Wednesday, April 17, 2024
End
Friday, April 19, 2024
Location: Japan
Booth Number: 5N-21

Visit Hovione’s booth at CPhI Japan - Booth #5N-21

CPHI Japan is a renowned meeting place for suppliers and buyers from the entire pharmaceutical supply chain, bringing leading pharma professionals together to network, learn and conduct vital face-to-face business.



Meet our team and learn more about Hovione’s latest technologies and innovations in drug development and how we can support your project.

 

Know how to overcome your solubility issues with the best scale-up science 

Through our proven expertise and leadership in particle engineering, we ensure that your inhalation and nasal therapies are engineered for success from start to finish.

Meet our experts and find out if Continuous Tableting is right for your product

The platform to identify the best performing and stable formulations for your drug

 

We look forward to seeing you at CPhI Japan. 

As a fully integrated CDMO we provide optimal solutions for your drug product with the right scale and flexibility. 

Schedule a meeting today.

And find out how we can support your project.


 

schedule a meeting

 

 

 

Find more about CPhI Japan 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026